MEDXHorizon Kinetics Medical ETF

Grow my money26y track recordRanked #2,414 of 2,969 in this goal

Seeks to provide long-term growth of capital.

By Horizon Kinetics · Launched 1999

Annual Cost

0.85%

#4,345 of 5,573 · expensive

Fund Size

$19M

#4,403 of 5,573 · small

Return (1Y)Goal

+28.7%

Track Record

26 years

#66 of 5,573 · established

Performance

Total-return NAV · USD

Growth of $10,000

$12,842+28.4%

Total-return NAV, USD. Net of fund fees, before tax.

What's inside

How Beacon categorizes this fund

Asset class

Equity

Region

Global

Strategy

Active selection

Sector

Health care

What it actually holds

By weight

Concentration

Top 10 holdings = 70.0% of fundconcentrated

Eli Lilly & Co

18.3%

AbbVie Inc

8.9%

US BANK MMDA - USBGFS 7USBGFS7

7.4%

Novartis AG

6.7%

AstraZeneca PLC

5.3%

Johnson & Johnson

5.0%

Ionis Pharmaceuticals Inc

5.0%

Alnylam Pharmaceuticals Inc

5.0%

Bristol-Myers Squibb Co

4.6%

Amgen Inc

3.9%

Asset allocation

Stocks

92.1%

Cash

7.7%

Other

0.2%

By sector

Healthcare

100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years

Volatility (1Y)

18.1%Moderate

Year-on-year price swings

Max drawdown

-23.1%Moderate

Worst peak-to-trough loss

Sharpe (3Y)

0.21Below average

Sortino (3Y)

0.29Moderate downside risk

Listing

Exchange: NASDAQ Global Select Market

Full fund details

Objective: Seeks to provide long-term growth of capital.
Strategy: Actively managed ETF investing primarily in common stocks and equity securities of U.S. and foreign companies in medical research and technology. Focuses on firms engaged in cancer research and drug development, evaluating their R&D expenditures and fundamentals.
Inception date: September 30, 1999
Fund family: Horizon Kinetics